City

Seoul (1)

Tampa (1)

Wellington (1)

Overall Status

Recruiting (3)

Phase

phase 1 (1)

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

Curocell Inc. (1)

H. Lee Moffitt Cancer Center and Research Institute (1)

Malaghan Institute of Medical Research (1)

Collaborator

Wellington Zhaotai Therapies Limited (WZTL) (1)

Intervention

cd19 targeted car t cell therapy (1)

crc01 (1)

cyclophosphamide (1)

cyclophosphamide and fludarabine lymphodepleting chemotherapy (1)

fludarabine (1)

pneumococcal conjugate vaccine (pcv13) (1)

wztl002-1 (1928t2z car-t cells) (1)

Study Documents

Intervention Type

biological (3)

drug (2)

Funder Type

Other (2)

Industry (1)

Study Type

Interventional (3)

transformed follicular lymphoma (tfl)

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL) Trial in

Recruiting

Diffuse Large-Cell Lymphoma
+3 more

Pneumococcal conjugate vaccine (PCV13)
CD19 targeted CAR T Cell Therapy

Tampa, Florida

Moffitt Cancer Center

May 31, 2022

Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) Trial in Seoul (CRC01,

Recruiting

Relapsed Large B-cell Lymphoma
+5 more

CRC01
+2 more

Seoul, Korea, Republic of

Samsung Medical Center

Apr 29, 2021

Lymphomas Non-Hodgkin's B-Cell, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal B-cell Lymphoma (PMBCL) Trial in

Recruiting

Lymphomas Non-Hodgkin's B-Cell
+5 more

WZTL002-1 (1928T2z CAR-T cells)
Cyclophosphamide and Fludarabine lymphodepleting chemotherapy

Wellington, New Zealand

Wellington Hospital, Capital & Coast District Health Board

Feb 18, 2020